Recommendations for DMT in POMS
International Pediatric Multiple Sclerosis Study Group Prompt initiation of a first-line DMT with moderate efficacy • Relapse rate is high in initial phases and correlated with a poor prognosis • Brain tissue shows more active inflammation in childhood • Despite the apparent clinical recovery from relapses due to better neuronal plasticity, cognitive impairment is frequent • Postponing treatment may have a negative impact on social activities and school performance
Heterogeneities across Europe concerning treatment DMT: disease-modifying therapy; POMS: pediatric onset MS Chitnis T, et al. Mult Scler. 2012 Jan;18(1):116-27
